China’s Coronary Stent Just Set the Template for IOL VBP Renewal, and the IOL Framework Is Still Missing
China’s coronary stent renewal published 13 May 2026. First IOL provincial agreements expire on 30 May. The methodology exists; the IOL instrument does not.
China has just done something it has been signalling for two years: the second renewal of national high-value device VBP is a temperate one. For ophthalmology, the awkward part is what was not published alongside it.
On 13 May 2026, the National Organisation Joint Procurement Office of High-Value Medical Consumables published the second-round renewal procurement document for coronary stents — file number GH-HD2026-1 (国家组织冠脉支架集中带量采购第二轮接续采购文件，编号GH-HD2026-1). On 20 May, the tender opened in Tianjin. The numbers are public: 15 companies bid, 30 products were submitted, all 15 companies were selected, 27 products won. 4,468 hospitals filed annual demand for approximately 2,726,093 alloy stents and 12,980 stainless-steel stents. The procurement cycle was extended through 30 June 2029.
Three details from GH-HD2026-1 matter for any audience watching renewal mechanics rather than the stent market itself.
First, the maximum effective bid price for alloy stents was raised from 848 RMB to 949 RMB per unit, an increase of approximately 11.91%. This is the first upward adjustment of a ceiling price in the history of high-value device VBP. Stainless-steel stents were added as a parallel category at 848 RMB. The signal is not subtle: after five years of one-way price pressure, the framework now has formal room for moderate price recovery.
Second, the renewal mechanism is an inquiry-based selection (询价模式) with tiered volume allocation. A bidder offering at or below the maximum effective price is selected; the proximity of its bid to the renewal reference price determines the share of contracted volume it receives. This replaces a regime in which the lowest bidder took disproportionate volume. The downside risk to the bidder is bounded by the published ceiling; the upside is governed by where they choose to land within the corridor.
Third, products newly approved during the procurement cycle may apply for supplemental selection under defined rules. Innovation has a stipulated re-entry path within the three-year cycle, rather than waiting for the next round.
These three pieces, a ceiling that can move up, tiered volume tied to bid position, and a window for new entrants, are the renewal methodology China has now published twice (coronary stents 2022 and 2026) and once for orthopaedic joints (GH-HD2024-1, executed from 10 November 2024). For spinal implants, the second-year arrangement was handled differently: a renewal-by-agreement model in which existing winning prices were extended through bilateral protocol updates rather than a new tender.
What is missing, and why is the timing awkward
The first batch of provincial IOL procurement agreements expires on 30 May 2026 for Guangdong, Shenzhen and Guangxi. The main national wave expires on 30 June 2026. As of 25 May, no renewal procurement document, no transitional notice, and no equivalent of GH-HD2026-1 has been published for intraocular lenses.
The 2026 work plan published by the National Healthcare Security Administration explicitly includes “the period-end renewal for intraocular lenses and sports medicine consumables” as a 2026 task. The intention is on the record. The instrument is not. This is the policy-execution gap that defines the next two weeks for IOL stakeholders.
For the coronary stent renewal, the gap between document publication (13 May) and contract expiry varied by region but was measured in weeks, not days. For IOL, the equivalent gap is now down to five days for the first batch of provinces and roughly five weeks for the main wave.
Two paths the renewal could take, and a third that is more likely
There are two published precedents and two distinct mechanics.
The coronary-stent and joint path is a published renewal procurement document with a new bidding round, a tiered ceiling, and a redefined cycle. It restarts price formation under a refreshed methodology.
The spinal-implant path is a renewal-by-agreement: provincial-level execution notices extend the existing winning prices into a second contract year under the original framework, without a new national tender. Guangdong’s second contract year for spinal implants ran from 15 March 2024 to 14 March 2025. Provincial extension notices in Hebei, Jiangxi and elsewhere followed in late 2024.
Neither precedent is likely to be a clean fit for IOL. The clinical product taxonomy makes a pure stent-style approach awkward: coronary stents resolve into two categories, alloy and stainless steel. IOLs resolve into at least six functionally distinct groups (monofocal non-toric, monofocal toric, bifocal, EDOF, trifocal, premium aspheric, and others). Within each group, post-operative outcomes are more tightly determined by product category than by manufacturer-level material differentiation. A toric monofocal IOL, regardless of brand or material, is expected to deliver a toric monofocal outcome; differentiation tends to operate at a second tier rather than the primary one. A single tiered-volume formula stretched across all six categories would either over-protect commodity groups or under-protect the premium ones.
The more probable structure, and this is OphthalLogix’s assumption, not a published rule, is a hybrid: functional grouping as the primary axis, with stent-style inquiry-based selection and tiered volume operating within each functional group. The renewal could publish six (or more) parallel price corridors, each with its own ceiling, reference price, and volume tiers. That structure would let monofocal categories compete on price-stability-versus-outcome inside one corridor, and premium categories (EDOF, trifocal) compete inside another, without forcing the two to share a single curve.
If this hypothesis is approximately right, the question for IOL manufacturers becomes which corridor matters most to them, and how aggressively they expect competitors inside that corridor to bid.
What price recovery looks like, qualitatively
Coronary stents are a single data point. The direction is clear (modest upward adjustment of the ceiling, with selection mechanics designed to discourage destructive bidding), but the magnitude, +11.91% on the alloy ceiling, does not translate mechanically to IOL.
On the supply side, domestic IOL manufacturers have absorbed approximately two and a half years of post-VBP price compression. Some categories retain operating margin headroom; some do not. Where the margin is intact, OphthalLogix expects domestic bidders to opt for a modest downward bid within the corridor to secure inclusion and volume rather than reach for an aggressive cut. Where margin is already thin, holding the line on price is the more likely strategy.
Multinational manufacturers carry brand equity, post-operative outcome stability, and surgeon familiarity into the renewal. In categories where reimbursement permits comparable corridors, a moderate downward adjustment to defend or expand volume, rather than a defensive hold, is the more rational position. The Chinese IOL volume base remains the largest single market opportunity for premium implants globally; entering the selection list at a moderate concession protects future positioning more efficiently than sitting outside it.
The renewal, when it arrives, will be a temperate one. Decisive further price compression beyond the first-round 60% average reduction is unlikely. Volume reallocation between domestic and multinational bidders, and within product categories, is where the real competitive action will sit.
What hospitals do in a transitional window
If the renewal framework arrives before 30 May or 30 June, none of this matters operationally. If it does not, hospital procurement faces a short window in which the previous contracts have lapsed, but no replacement framework is in effect.
Based on prior cataract surgical practice in tertiary centres, the dominant institutional response is to continue routine ordering under the existing framework prices in reduced batches, rather than to suspend cataract surgery. Procurement teams typically contact provincial medical insurance bureaus first; in the absence of new guidance, the operational default is to maintain throughput. Excess inventory accumulated in this window is usually returnable to suppliers once a new framework is published.
Where the operational picture diverges is at the premium end. For monofocal and bifocal categories, the substitution set is broad; if a specific SKU becomes briefly unavailable, alternatives are available within a comparable price band, and surgeons can resolve substitution in pre-admission planning. For the trifocal and EDOF categories, the substitution set is narrower. The realistic options, in approximate descending order of frequency: postpone the elective procedure, substitute with a bifocal at the patient’s consent, or, rarely, proceed with the original implant under patient self-payment. The last option is operationally weak, because once a new framework publishes a lower official price than what the patient paid out-of-pocket, the patient-relationship cost outweighs the case revenue.
None of this is improvised at the operating table. Cataract surgery is elective and short-cycle; the IOL is confirmed at admission, sometimes at the outpatient stage. Substitution decisions are made before the patient is on the table, not during the procedure.
What investors and market-access teams should be doing this week
For listed domestic IOL manufacturers (Eyebright Medical 688050, Haohai Biotech 688366), the renewal mechanics, not the headline price, will determine the 2027 revenue trajectory. Whether the renewal uses the stent-style inquiry mechanism or the spinal-style agreement extension changes, which scenarios should be modelled?
For multinational market-access teams, the present week is for scenario design rather than execution. Three pricing scenarios, moderate hold, moderate downward adjustment to secure tiered volume, and defensive aggressive cut to expand share, should each have a defined trigger condition tied to whichever framework variant is published.
For hospital procurement teams, the conservative operational default holds: maintain existing throughput at existing prices, in reduced batches, with supplier return arrangements clarified for any accumulated inventory.
A line worth holding
The most reliable thing that can be said about this moment is that the methodology now exists in published form. Three iterations of stent renewals, one orthopaedic renewal, and one spinal agreement extension. The instruments are on the shelf. The IOL framework has not been published yet. Whether the next two weeks close that gap, or whether the first batch of provinces operate in a brief documentary vacuum, will be visible to anyone watching the procurement office website.
Either outcome is informative. The publication-or-silence of the next two weeks is the most useful single data point an IOL stakeholder will get this quarter.
This content is for informational purposes only and does not constitute legal, regulatory, investment, medical, or commercial advice. China's healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. Where this content includes working assumptions or hypotheses about future policy mechanics, these are framed as assumptions, not predictions of fact, and should be retested against the actual published framework.